The synthesis of a series of N,N’-bisquinolylmethyl-2-alkyl and N-quinolylmethyl-N’-naphthylmethyl-2-alkyl substituted imidazolium salts will be presented. Characterization techniques will include <sup>1</sup>H NMR, <sup>13</sup>C NMR, mass spectrometry, and single crystal X-ray crystallography of select derivatives. The anticancer activity against a variety of non-small cell lung cancer lines (NCI-H460, NCI-H1975, HCC827, NCI-A549) will be discussed. Quinolyl derivatives are of interest to aid with increasing the aqueous solubility of previous N,N’-bisnaphthylmethyl-2-alkyl substituted imidazolium salts with high anticancer activity. Lung cancer is the leading cause of cancer related deaths in the United States. Current chemotherapy agents used for the treatment of lung cancer include platinum based drugs in combination with organic based drugs. However, the 5 year survival rate in lung cancer patients remains low when compared with other cancers. Napthylmethyl and quionolylmethyl substituted imidazolium salts are promising candidates for use as new chemotherapy agents which is necessary for the treatment of lung cancer. Finding new therapeutics is essential to increase the survival rate and quality of life for lung cancer patients.

N,N’-bisquinolylmethyl-2-alkyl and N-quinolylmethyl-N’-naphthylmethyl-2-alkyl substituted imidazolium salts as potential therapeutics for the treatment of lung cancer: Synthesis, characterization, and in vitro anticancer activity

249th National Meeting (2015)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.